ERBB2 and breast carcinoma: To analyze the expression levels and subcellular localization of SMURF2 in breast tumors, we conducted IHC analyses on three different breast carcinoma TMAs: BR804a, composing primary breast carcinoma and adjacent normal tissues; BR10011a, consisting of invasive breast tumors, most of which are triple-negative (not expressing estrogen, progesterone and HER2/neu receptors); and BR10010c, incorporating invasive and matching metastatic tissues.